Can steroids save lives in severe pneumonia? new trial aims to find out

NCT ID NCT07152587

Not yet recruiting Disease control Sponsor: Qingyuan Zhan Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This trial tests whether low or moderate doses of the steroid methylprednisolone can reduce deaths in patients with severe community-acquired pneumonia. It will enroll 1500 ICU patients with pneumonia caused by adenovirus or Pneumocystis jirovecii. The study uses an adaptive design to assign more patients to the better-performing dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Methylprednisolone (a steroid)

What this could lead to

If successful, this could identify the best steroid dose to reduce deaths from severe pneumonia caused by certain viruses or fungi.

What could go wrong

This is an early-stage trial with only 1500 participants, and steroids can have serious side effects like infections or bleeding. The results may not apply to all pneumonia patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE COMMUNITY-ACQUIRED PNEUMONIA (SCAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumocystosis pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE COMMUNITY-ACQUIRED PNEUMONIA (SCAP)